| Vol. 14.14 – 22 April, 2022 |
| |
|
|
| Scientists found that mitochondrial apoptosis pathway was essential for efficient NK killing, especially at physiologically relevant effector-to-target ratios. [Cell] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| In mouse models, vitamin E (VitE) increased immune checkpoint therapy antitumor efficacy, which depended on dendritic cells (DCs). VitE entered DCs via SCARB1 receptor and restored tumor-associated DCs’ functionality by directly binding to and inhibiting protein tyrosine phosphatase SHP1. [Cancer Discovery] |
|
|
|
| Investigators used mouse models of DOCA+salt treatment and adoptive transfer of CD8+ T cells (CD8T) from hypertensive animals to normotensive animals in in vivo studies. [Circulation Research] |
|
|
|
| Researchers investigated the relative contribution of potential ligands, stable peptide-MHC class II complexes and fibrinogen-like protein 1, to lymphocyte activation gene-3 (LAG-3) activity in vitro and in vivo. [Immunity] |
|
|
|
| The authors found that genetic deletion of mitochondrial pyruvate carrier (MPC) drove CD8+ T cell differentiation toward a memory phenotype. In the tumor microenvironment, MPC was essential for sustaining lactate oxidation to support CD8+ T cell antitumor function. [Cell Metabolism] |
|
|
|
| Investigators found that regulatory T cell with an effector phenotype (eTreg) cell expression of PD-1 acted as a sensor to rapidly tune the pool of eTreg cells at homeostasis and during inflammatory processes. [Nature Immunology] |
|
|
|
| Scientists showed that LAG3 moved to the immunological synapse and associated with the T cell receptor (TCR)-CD3 complex in CD4+ and CD8+ T cells, in the absence of binding to major histocompatibility complex class II — its canonical ligand. [Nature Immunology] |
|
|
|
| Using systemically delivered oncolytic viruses (OVs) and CAR T cells in immunocompetent mouse models, the authors defined a mechanism by which OVs could potentiate CAR T cell efficacy against solid tumor models of melanoma and glioma. [Science Translational Medicine] |
|
|
|
| Scientists observed that a high frequency of brain-infiltrating CD8+ T cells exhibited a memory T cells-like phenotype in human autoimmune encephalitis. [Science Translational Medicine] |
|
|
|
| Genetic deletion of pyruvate kinase muscle 2 (PKM2) in myeloid cells or limiting its nuclear translocation reduced atherosclerosis by suppressing inflammation and enhancing efferocytosis. [Circulation Research] |
|
|
|
| Researchers used single-cell technology and in vitro assays to interrogate the immune microenvironment of human coronary atherosclerotic plaque at different stages of maturity. [Circulation Research] |
|
|
|
| The authors contextualized macrophage heterogeneity across mouse tissues and inflammatory conditions, specifically aiming to define a common framework of macrophage activation. [Science Immunology] |
|
|
|
| Investigators established a role for CD8+ T cell-dependent anti-tumor immunity in mediating sex differences in tumor aggressiveness, which was driven by the gonadal androgen but not sex chromosomes. [Science Immunology] |
|
|
|
|
| Scientists describe the essentials of antigen processing and presentation and how the source proteins for these antigens are tagged for degradation, destroyed and ultimately displayed as peptides in complex with major histocompatibility complex molecules for T cell recognition. [Nature Reviews Immunology] |
|
|
|
| Understanding the complex interplay between metabolic and inflammatory pathways in synovial cells in rheumatoid arthritis will provide insight into the underlying mechanisms of disease pathogenesis. [Nature Reviews Rheumatology] |
|
|
|
| The authors examine the dual functions of CD36 in a variety of immune cells, especially macrophages and T cells. [Journal of Experimental Medicine] |
|
|
|
|
| Dragonfly Therapeutics, Inc. announced an expansion of its research collaboration with AbbVie to discover and develop Dragonfly’s novel immunotherapies for new targets in autoimmune and fibrotic diseases. [Dragonfly Therapeutics, Inc. (Cision US, Inc.)] |
|
|
|
|
| May 22 – 25, 2022 Denver, Colorado, United States |
|
|
|
|
|
| Uppsala University – Uppsala, Sweden |
|
|
|
| Fred Hutchinson Cancer Center – Seattle, Washington, United States |
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| University Hospital Carl Gustav Carus Dresden – Dresden, Germany |
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
|